Thursday, July 07, 2011

Adaptive Licensing for Drug Approval

From this year’s Drug Information Association (DIA) annual conference in Chicago, I learned a new concept of “Adaptive Licensing”. According to, “in the past five years, a wave of proposals for reform of drug licensing has emerged in the EU, US, and Canada under the labels of staggered approval, adaptive licensing, managed entry and progressive authorization. Through iterative phases of information gathering followed by regulatory evaluation and correction, these approaches seek to align licensing decisions on market access of drugs with emerging information on benefits and harms of drugs as actual used. It is hoped that this approach will provide patients with earlier access to innovative drugs to address unmet medical needs, better management of known risks, and improved detection of unanticipated adverse effects that emerge in use. “

The current drug licensing process is called ‘phased approach’ which requires the sponsors to conduct a series of clinical trials from phase I to phase III to establish the safety/tolerability and to confirm the efficacy before the regulatory agencies can consider the approval for marketing authorization of a product. This phased approach and the purpose of each phase of the clinical trial are discussed in this free web article. Recently, with the adaptive design concept, we are trying to break the traditional phased approach. The seamless phase II/III studies or seamless phase I/II studies have been much discussed and debated. Even with adaptive design, before a drug can be approved, a series of clinical trials are still required. Let’s now call “learning and confirming”: from early trial for learning to late stage trial for confirmation of the safety and efficacy with Adequate and well-controlled clinical study(ies) (A&WC).

With the phased drug approval approach, there will be a magic moment during the drug approval process. This magic moment is the regulatory reviewer’s action date (or decision date) - The date tells when a regulatory action, such as an original or supplemental approval, takes place. The regulatory agencies will be based on the review of data from pre-marketing clinical studies to make a decision of approving or not approving a production for market authorization. If the efficacy and safety have been demonstrated, the product is approved; if the efficacy and safety have not been sufficiently demonstrated, additional clinical studies may be requested; if the efficacy and safety are not demonstrated, the application of market authorization will be denied.

The adaptive licensing is trying to remove this magic moment from the drug approval process and instead considers the drug licensing as a continuous process. Whether or not a product should be authorized for marketing depends on the risk-benefit ratio. When the benefit outweighs the risk, the product should be approved; when the risk outweighs the benefit, the product should not be approved. For an approved product, if the benefit/risk ratio becomes unfavorable, the product should be withdrawn from the market. I liken this continuous adaptive drug licensing process to the p-value assessment in statistics. The magic moment is like the magic number of p=0.05 (p-value should be a continuous number and p=0.051 (not significant) may not be different from p=0.049 (significant)).

It looks like EU is pioneering in implementing the adaptive licensing. EMA has started to work on Adaptive Licensing to Reach Roadmap Goals (Roadmap to 2015) . However, in US, there is a similar program called “Accelerated Approval of New Drugs for Serious or Life-Threatening Illnesses”. With this program, “FDA may grant marketing approval for a new drug product on the basis of adequate and well-controlled clinical trials establishing that the drug product has an effect on a surrogate endpoint that is reasonably likely, based on epidemiologic, therapeutic, pathophysiologic, or other evidence, to predict clinical benefit or on the basis of an effect on a clinical endpoint other than survival or irreversible morbidity. Approval under this section will be subject to the requirement that the applicant study the drug further, to verify and describe its clinical benefit, where there is uncertainty as to the relation of the surrogate endpoint to clinical benefit, or of the observed clinical benefit to ultimate outcome. Postmarketing studies would usually be studies already underway. When required to be conducted, such studies must also be adequate and well-controlled. The applicant shall carry out any such studies with due diligence.”

However, the recent debates on whether or not Avastin (Bevicuzmab) should be withdrawn from the market for breast cancer demonstrated how difficult to implement this program. Based on the established rule, if a drug is approved through ‘accelerated approval’, the approval is conditional and can be withdrawn from the market if the drug is later showed to be ineffective or with unfavorable benefit/risk ratio. Avastin in breast cancer case just showed how difficult to withdraw a product due to ineffectiveness. In even worse situation, the drug companies may not fulfill the commitment to finish the follow-up studies. There have been several cases of marketing withdrawal due to safety concerns (for example, Vioxx), but it seems to be more difficult to withdraw a product from the market due to the efficacy concern.

Adaptive licensing may be the future direction for drug approval process; however, many issues need to be considered and resolved before this new process can be implemented.

No comments: